We have previously demonstrated that Notch3-specific inhibition by Notch3 specific siRNA and γ-secretase inhibitor (GSI) sensitizes PTX-resistant ovarian cancer cells to paclitaxel treatment [5]. This evidence concerns the gene NOTCH3 and ovarian carcinoma.